您的位置: 首页 > 农业专利 > 详情页

Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor
专利权人:
The General Hospital Corporation;Aperisys, Inc.
发明人:
Mark C. Poznansky,Stephen J. McCormack,Michael Callahan,Jeffrey A. Gelfand,Huabiao Chen,Patrick Reeves
申请号:
US16612109
公开号:
US20200093789A1
申请日:
2018.05.10
申请国别(地区):
US
年份:
2020
代理人:
摘要:
The present invention relates to methods and compositions for treating cancer and enhancing the immune response against cancer cells using the combination of an inhibitor of CXCL12 signaling and an immune checkpoint inhibitor. The invention further relates to compositions and kits of parts comprising an inhibitor of CXCL 12 signaling and an immune checkpoint inhibitor for use in the methods of the invention.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充